Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Despite changes over the years, the legacy of Jackson Street continues to resonate, with a new generation of musicians and ...

Just a two-year-old when his family moved to Chicago from Mississippi during the Great Depression, Johnson had recently opened a gleaming new 30,000 sq. ft. manufacturing facility on two acres of ...